Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma

NCT07371923 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG: Zanubrutinib+Pola-R-CHP

Sponsor

Beijing Tongren Hospital